Get started
Author

Geert Spierenburg

Observed names: Spierenburg, G., Spierenburg, Geert
ORCID: 0000-0002-0236-7338
Observed ORCID: 0000-0002-0236-7338
OpenAlex ID: A5089410993
The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
2021 · TOPP Study Group, Nicholas M. Bernthal, et al. · Orphanet Journal of Rare Diseases · 49
PDF
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours
2022 · Geert Spierenburg, Peter Grimison, et al. · European Journal of Cancer · 36
PDF
Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2022 · David G.P. van IJzendoorn, Magdalena Matusiak, et al. · Clinical Cancer Research · 35
PDF
Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches
2022 · Geert Spierenburg, Lizz van der Heijden, et al. · Expert Opinion on Therapeutic Targets · 30
MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
2023 · Geert Spierenburg, Carlos Suevos Ballesteros, et al. · Insights into Imaging · 28
PDF
Management of tenosynovial giant cell tumour of the foot and ankle
2021 · Geert Spierenburg, Sarah Tamar Lancaster, et al. · The Bone & Joint Journal · 21
Systemic Metal Ion Concentrations in Patients With Hip and Knee Megaprostheses: A Prospective Cohort Study
2022 · Kiki Q. de Smidt, Geert Spierenburg, et al. · Arthroplasty Today · 17
Surgical management of 144 diffuse‐type TGCT patients in a single institution: A 20‐year cohort study
2022 · Geert Spierenburg, Lizz van der Heijden, et al. · Journal of Surgical Oncology · 15
PDF
A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
2022 · Nicholas M. Bernthal, John H. Healey, et al. · Journal of Surgical Oncology · 13
PDF
Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study
2024 · Geert Spierenburg, Eric L. Staals, et al. · European Journal of Surgical Oncology · 11
PDF
Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets
2023 · Lizz van der Heijden, Geert Spierenburg, et al. · Journal of Surgical Oncology · 8
PDF
One-Stage Synovectomies Result in Improved Short-Term Outcomes Compared to Two-Stage Synovectomies of Diffuse-Type Tenosynovial Giant Cell Tumor (D-TGCT) of the Knee: A Multicenter, Retrospective, Cohort Study
2023 · Geert Spierenburg, Floortje Verspoor, et al. · Cancers · 4
PDF
Supplementary Table from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
PDF
Supplementary Figure from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
PDF
Supplementary Table from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
Supplementary Figure from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
Data from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
Data from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
2023 · David G.P. van IJzendoorn, Magdalena Matusiak, et al.
Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.
2020 · Nicholas M. Bernthal, Geert Spierenburg, et al. · Journal of Clinical Oncology
The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective real-world study
2020 · Nicholas M. Bernthal, Geert Spierenburg, et al.
PDF
Works count: 23
Citation count: 267
H-index: 10
I10-index: 10
Year
Topic
Type